IBS Explained: What’s Actually Happening in Your Gut – and Why It’s More Than “Just Stress”

Irritable bowel syndrome (IBS) is one of the most common gastrointestinal conditions in the world, affecting between 5% and 15% of the global population – approximately 400 million people. It’s also one of the most misunderstood, most dismissed, and most frustrating conditions to live with.

People with IBS are told their gut is “normal” on tests, that it’s “just stress,” or – in a variation of the same dismissal – that it’s “all in their head.” This framing is both scientifically outdated and harmful. IBS involves real, measurable changes in gut function, gut-brain communication, pain processing, and the gut microbiome. It significantly impairs quality of life, affects work productivity, disrupts relationships, and in many people produces daily symptoms they’ve been managing for years with little clinical support.

Understanding what IBS actually is – and what the evidence shows about treating it – changes the picture considerably.

What IBS Is

IBS is a functional gastrointestinal disorder – meaning it’s defined by symptoms rather than structural or biochemical abnormalities detectable on standard tests. The gut looks normal on endoscopy and biopsy, blood tests are typically normal, and imaging is unremarkable. Yet the gut is functioning abnormally in ways that cause real, significant symptoms.

IBS is diagnosed using the Rome IV criteria (the current international diagnostic standard, updated in 2016):

Recurrent abdominal pain, on average at least one day per week in the last three months, associated with two or more of the following:

• Related to defecation (pain improves or worsens with a bowel movement)
• Associated with a change in frequency of stool
• Associated with a change in form (appearance) of stool

Symptoms must have started at least six months before diagnosis, and other conditions (IBD, coeliac disease, colorectal cancer) must be excluded.

IBS subtypes based on predominant stool pattern:

• IBS-C (constipation-predominant): More than 25% of bowel movements are hard or lumpy stools; fewer than 25% are loose or watery
• IBS-D (diarrhoea-predominant): More than 25% of bowel movements are loose or watery; fewer than 25% are hard or lumpy
• IBS-M (mixed): More than 25% of bowel movements are both hard/lumpy and loose/watery
• IBS-U (unclassified): Doesn’t fit the other three categories

Subtype matters for treatment – many interventions are subtype-specific.

What’s Actually Happening in IBS

IBS is not a single mechanism – it’s a disorder with multiple contributing biological abnormalities that vary between patients. This is why it’s heterogeneous and why what helps one person doesn’t help another.

Visceral Hypersensitivity

The most consistently documented biological feature of IBS is visceral hypersensitivity – an abnormally low pain threshold in the gut. When the intestine is distended (inflated with a balloon in research settings, or distended by gas and stool in daily life), people with IBS experience pain at significantly lower volumes than healthy controls.

This isn’t imagined sensitivity. It reflects real changes in how gut signals are processed: altered pain receptor sensitivity in the gut wall, altered spinal cord processing of gut signals, and altered brain processing of pain signals from the gut. The gut-brain axis is dysregulated – and the downstream result is genuine pain from stimuli that wouldn’t cause pain in a gut without this sensitisation.

Altered Gut Motility

Gut motility – the speed and pattern of intestinal contractions – is abnormal in IBS, contributing to constipation, diarrhoea, or alternating patterns. The colon in IBS-D may contract too rapidly, reducing water absorption and producing loose stool. In IBS-C, colonic transit is slowed. This motility dysfunction is driven by altered enteric nervous system activity and gut-brain axis signalling.

Gut-Brain Axis Dysregulation

The gut and brain communicate continuously through the vagus nerve, the enteric nervous system, the HPA (stress) axis, and gut-derived hormones and neurotransmitters. In IBS, this bidirectional communication is disrupted.

Psychological stress reliably worsens IBS symptoms through these pathways – not because IBS is psychological, but because stress hormones directly affect gut motility, gut barrier function, visceral sensitivity, and the immune response in the gut wall. This explains why IBS worsens with anxiety and stress, improves with psychological interventions, and yet produces real gut physiological changes.

Altered Gut Microbiome

Multiple studies find distinct microbiome patterns in people with IBS compared to healthy controls – typically reduced diversity, altered proportions of specific species, and altered SCFA production. Post-infectious IBS (which develops after gastroenteritis, particularly bacterial gastroenteritis) is one of the best-documented subtypes, occurring in 5-25% of people after acute gastrointestinal infections. The infection appears to trigger lasting gut microbiome changes and immune activation that drive ongoing IBS symptoms.

Low-Grade Mucosal Inflammation and Immune Activation

Despite normal-appearing biopsies on routine histology, IBS gut mucosa shows subtle immune activation – increased mast cells and activated immune cells in the gut wall. Mast cells are adjacent to gut nerves, and their activation releases mediators (histamine, tryptase, prostaglandins) that directly sensitise visceral pain nerves. This immune-neural interaction is a significant driver of visceral hypersensitivity in a subset of IBS patients.

Gut Barrier Dysfunction

Increased intestinal permeability – “leaky gut” in its clinically meaningful sense – has been documented in a subset of IBS patients, particularly those with post-infectious IBS and IBS-D. Increased permeability allows bacterial products to access the immune cells in the gut wall, potentially driving the low-grade inflammation and immune activation described above.

IBS vs IBD: A Critical Distinction

IBS and inflammatory bowel disease (IBD – Crohn’s disease and ulcerative colitis) are frequently confused by patients and sometimes initially by clinicians. They are fundamentally different conditions:

Faecal calprotectin – a stool test – is a very useful non-invasive way to distinguish IBS from IBD, as it’s elevated in gut inflammation (IBD) but normal in IBS. A normal faecal calprotectin in a patient with typical IBS symptoms strongly supports IBS rather than IBD.

Who Gets IBS

IBS affects people of all ages worldwide, with some consistent patterns:

• More common in women than men (approximately 2:1 ratio in most studies)
• Most commonly diagnosed between ages 20-40
• Onset after acute gastrointestinal infection (post-infectious IBS) is a well-defined subset
• Anxiety and depression are strongly associated – present in approximately 50-90% of people with IBS seeking care (though many IBS patients in the community don’t have these comorbidities)
• Family clustering suggests genetic susceptibility, though no single gene has been identified
• Higher prevalence in higher-income countries and urban settings, though IBS is found in all populations studied

Diagnosis: What Tests Are Needed

IBS is a clinical diagnosis – based on symptoms meeting Rome IV criteria combined with the exclusion of other conditions.

Tests that should be performed to exclude other diagnoses:

• Full blood count (FBC/CBC) – to exclude anaemia suggesting bleeding or malabsorption
• C-reactive protein (CRP) or ESR – elevated in IBD, typically normal in IBS
• Faecal calprotectin – highly useful for distinguishing IBS from IBD
• Thyroid function tests (TSH) – hypothyroidism causes constipation; hyperthyroidism causes diarrhoea
• Coeliac serology (tTG-IgA + total IgA) – coeliac disease presents identically to IBS-D in many cases; exclusion is essential
• Consider: stool microscopy and culture if recent travel history or infection symptoms

Colonoscopy is not routinely required for straightforward IBS presentation in younger patients. It becomes necessary if there are red flag features:

• Blood in stool
• Unintentional weight loss
• Fever
• Onset after age 50
• Anaemia
• Nocturnal symptoms (waking from sleep with symptoms)
• Family history of colorectal cancer or IBD

Treatment: The Evidence Base

IBS has no cure, but multiple evidence-based treatments significantly reduce symptoms and improve quality of life. Treatment should be tailored to the predominant subtype and the individual’s specific symptom profile.

Dietary Approaches

Low-FODMAP diet: The best-evidenced dietary intervention for IBS. FODMAPs (Fermentable Oligosaccharides, Disaccharides, Monosaccharides And Polyols) are fermentable carbohydrates that produce gas and draw water into the gut. Reducing them reduces symptoms in approximately 50-70% of IBS patients.

The low-FODMAP diet is a three-phase process:

1. Elimination phase (4-8 weeks): All high-FODMAP foods are removed
2. Reintroduction phase: FODMAP groups are systematically reintroduced to identify personal triggers
3. Personalisation: A long-term adapted diet based on individual tolerances

The low-FODMAP diet should be conducted with a dietitian’s guidance – without structure, it can produce nutritional inadequacy and unnecessary dietary restriction. The goal is to identify specific triggers, not to eliminate FODMAPs permanently.

Fibre: For IBS-C, soluble fibre (psyllium/ispaghula husk) has the best evidence – it bulks stool and improves transit without the excess gas production of insoluble fibre (bran), which can worsen IBS symptoms. For IBS-D, high-fibre intake may worsen symptoms initially.

Gluten: Some people with IBS improve on a gluten-free diet, even without coeliac disease. This may reflect FODMAP reduction (wheat is a high-FODMAP food, so a gluten-free diet often reduces FODMAPs) rather than gluten sensitivity specifically.

Gut-Brain Axis Therapies

Psychological therapies have among the strongest evidence bases of any IBS treatment – and specifically through gut-brain axis mechanisms, not because IBS is “psychological”:

Cognitive Behavioural Therapy (CBT) for IBS: Multiple randomised controlled trials and a 2022 Lancet Gastroenterology & Hepatology trial demonstrate significant and durable symptom reduction. CBT for IBS addresses the thought patterns and behaviours that amplify gut symptoms through gut-brain axis pathways.

Gut-directed hypnotherapy: Counter-intuitive but well-evidenced – reduces visceral hypersensitivity and improves gut motility through brain-gut pathways. The Manchester protocol (gut-directed hypnotherapy, not general hypnotherapy) has the most evidence, showing symptom improvement in approximately 60-70% of patients with durable effects.

Mindfulness-based stress reduction (MBSR): Evidence supports significant symptom improvement.

Medications

Antispasmodics (mebeverine, hyoscine, peppermint oil): Reduce gut spasm and pain. Peppermint oil capsules (enteric-coated) have good evidence for IBS abdominal pain – their mechanism involves calcium channel blockade in gut smooth muscle.

Laxatives for IBS-C: Osmotic laxatives (polyethylene glycol/macrogol, lactulose) improve stool consistency and frequency. Macrogol has good safety evidence for long-term use.

Linaclotide and plecanatide: For IBS-C specifically – increase fluid secretion into the gut, improving transit. Prescription medications with good trial evidence.

Loperamide: For IBS-D – reduces stool frequency and urgency. OTC in most countries.

Rifaximin: A non-absorbable antibiotic that reduces bacterial fermentation in the gut. Approved in some countries for IBS-D. Targets a proposed microbiome-driven mechanism.

Low-dose antidepressants: Not for depression in this context, but for their direct gut effects. Tricyclic antidepressants (e.g. amitriptyline 10-25mg) reduce visceral hypersensitivity and slow transit, useful for IBS-D with pain. SNRIs (e.g. duloxetine) may help IBS-C with pain. These are used at doses below those used for depression.

Probiotics: Specific strains have modest evidence for IBS – particularly Bifidobacterium infantis 35624 and certain Lactobacillus strains. The evidence is more positive than for general gut health use, but effect sizes are modest and optimal strains/doses aren’t established.

Frequently Asked Questions

Is IBS the same as having a sensitive stomach? “Sensitive stomach” is a colloquial term that sometimes refers to IBS and sometimes to other conditions. Clinically, IBS involves documented visceral hypersensitivity, altered motility, and gut-brain axis changes. It’s a recognised medical condition with diagnostic criteria and treatment guidelines, not simply a constitutional tendency.

Can IBS turn into IBD or bowel cancer? No – IBS does not progress to inflammatory bowel disease or colorectal cancer. IBS doesn’t cause structural damage to the gut. However, having IBS doesn’t protect against developing these other conditions, so appropriate screening (colonoscopy from age 45-50 or as locally recommended) should continue in people with IBS.

Why does stress make IBS worse? Through direct physiological mechanisms, not imagination. Stress activates the HPA axis (releasing cortisol) and the sympathetic nervous system, both of which directly alter gut motility, gut barrier function, and visceral pain thresholds. The gut has as many neurons as the spinal cord and is in constant communication with the brain – psychological states produce measurable gut physiological changes.

Is the low-FODMAP diet for life? No – and it shouldn’t be. The low-FODMAP diet is a diagnostic and therapeutic tool, not a permanent eating pattern. The reintroduction and personalisation phases identify which specific FODMAP groups trigger symptoms for that individual. Most people find they can tolerate many FODMAPs and need to restrict only a subset – reducing the burden of the diet considerably.

Can IBS be cured? There is no established cure, but IBS symptoms fluctuate and many people experience significant periods of remission. Approximately 30-50% of IBS patients report substantial symptom improvement over 5 years. Effective management – combining dietary approaches, gut-brain axis therapies, and where necessary medication – can produce dramatically better quality of life even without cure.

Disclaimer

This article is for educational purposes only and does not constitute medical advice. Symptoms of IBS overlap with several other conditions requiring different treatment. A proper diagnosis from a qualified healthcare provider is essential before beginning treatment. Red flag symptoms (blood in stool, weight loss, anaemia, fever, onset after 50) require urgent medical evaluation.

References

1. Lacy BE, Mearin F, Chang L, et al. Bowel disorders. Gastroenterology. 2016;150(6):1393-1407. https://doi.org/10.1053/j.gastro.2016.02.031
2. Ford AC, Sperber AD, Corsetti M, Camilleri M. Irritable bowel syndrome. The Lancet. 2020;396(10263):1675-1688. https://doi.org/10.1016/S0140-6736(20)31548-8
3. Ng QX, Soh AYS, Loke W, Lim DY, Yeo WS. The role of inflammation in irritable bowel syndrome (IBS). Journal of Inflammation Research. 2018;11:345-349. https://doi.org/10.2147/JIR.S174982
4. Holtmann GJ, Ford AC, Talley NJ. Pathophysiology of irritable bowel syndrome. The Lancet Gastroenterology & Hepatology. 2016;1(2):133-146. https://doi.org/10.1016/S2468-1253(16)30023-1
5. Everitt H, Landau S, O’Reilly G, et al. Cognitive behavioural therapy for irritable bowel syndrome (ACTIB): a multicentre randomised trial. The Lancet Gastroenterology & Hepatology. 2019;4(11):863-872. https://doi.org/10.1016/S2468-1253(19)30243-2
6. Staudacher HM, Whelan K. The low FODMAP diet: recent advances in understanding its mechanisms and efficacy in IBS. Gut. 2017;66(8):1517-1527. https://doi.org/10.1136/gutjnl-2017-313750
7. World Gastroenterology Organisation. WGO global guidelines: irritable bowel syndrome. 2015. https://www.worldgastroenterology.org/guidelines/irritable-bowel-syndrome-ibs
8. NICE (National Institute for Health and Care Excellence). Irritable bowel syndrome in adults: diagnosis and management. 2017. https://www.nice.org.uk/guidance/cg61
9. Quigley EMM. Gut bacteria in health and disease. Gastroenterology & Hepatology. 2013;9(9):560-569.
10. Whorwell PJ, Prior A, Faragher EB. Controlled trial of hypnotherapy in the treatment of severe refractory irritable-bowel syndrome. The Lancet. 1984;2(8414):1232-1234. https://doi.org/10.1016/S0140-6736(84)92793-4